Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Role of Btla/Hvem Network in Development of Gastric Cancer Publisher Pubmed



Azarafza M1 ; Tehrani M1, 2 ; Valadan R2 ; Maleki I4 ; Mohammad Mehdi Ghaffarihamedani S5 ; Ghanadan A6 ; Alizadehnavaei R7 ; Ajami A1, 2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  2. 2. Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  3. 3. Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran
  4. 4. Department of Gastroenterology, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
  5. 5. Department of Surgery, Mazandaran University of Medical Sciences, Sari, Iran
  6. 6. Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Tehran, Iran
  7. 7. Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Source: Human Immunology Published:2022


Abstract

The immunopathological mechanism underlying intestinal metaplasia and gastric cancer remain incompletely understood. Regarding the role of B- and T-lymphocyte attenuator (BTLA) / herpesvirus entry mediator (HVEM) in tumorigenesis, this research was conducted to determine the BTLA/HVEM expression in development of gastric cancer. Gastric biopsy and peripheral blood was drawn from 32 non-ulcer dyspepsia (NUD) as control group, 19 intestinal metaplasia (IM), and 63 gastric cancer (GC). BTLA/HVEM expression were analyzed by immunohistochemistry and quantitative real-time polymerase chain reaction. Soluble HVEM (sHVEM) and anti-Helicobacter pylori IgG antibody were assessed by ELISA. Our result showed that BTLA mRNA and protein were significantly increased in advanced stages of gastric cancer. HVEM was higher only at the protein level in the GC group. The sHVEM concentration was also higher in the GC group than in the NUD groups. In addition, we observed H. pylori-positive samples had a lower H-score of HVEM than H. pylori-negative ones. These results suggest that BTLA/HVEM/sHVEM inhibitory pathway is involved in immune regulation and progression of gastric cancer. Therefore, this inhibitory pathway might be a therapeutic target to further immunotherapy of gastric cancer. © 2022 American Society for Histocompatibility and Immunogenetics
Related Docs
View other Related Docs
1. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
2. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
3. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)
4. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
5. Therapeutic and Immunomodulatory Potentials of Mesenchymal Stromal/Stem Cells and Immune Checkpoints Related Molecules, Biomarker Research (2024)
6. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
7. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
8. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (12)
Hamid Reza Mirzaei (2)
Other Related Docs
9. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
10. Gene-Knocked Out Chimeric Antigen Receptor (Car) T Cells: Tuning up for the Next Generation Cancer Immunotherapy, Cancer Letters (2018)
11. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
12. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
13. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
14. Immune Checkpoint Inhibitors Therapy As the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape, Critical Reviews in Oncology/Hematology (2024)
15. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
16. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity, IUBMB Life (2021)
17. Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-Ctla-4 and Doxil Combination Therapy, International Journal of Nanomedicine (2020)
18. Tumor Immunology, Clinical Immunology (2022)
19. Chitosan: A Compound for Drug Delivery System in Gastric Cancer-A Review, Carbohydrate Polymers (2020)
20. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)
21. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
22. The Association Between Dietary Inflammatory Potential and Gastric Cancer: A Case Control Study, Nutrition and Cancer (2022)
23. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
24. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
25. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
26. Immune Checkpoint Inhibition for Pancreatic Cancer, Acta Medica Iranica (2023)
27. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
28. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
29. Precision Medicine in Non Communicable Diseases, International Journal of Molecular and Cellular Medicine (2019)
30. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
31. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
32. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
33. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)